Back to search results
Bridget Keenan
Bridget Keenan

Bridget Keenan, MD, PhD

Cancer Immunotherapy Clinic
1825 Fourth St., Fifth Floor,
San Francisco, CA 94158
(415) 353-2421
Virtual visits available
Virtual visits available
Cancer Immunotherapy Clinic
1825 Fourth St., Fifth Floor,
San Francisco, CA 94158
(415) 353-2421

About me

Pronouns: She | Her | Hers

Insurance plan info

Dr. Bridget Keenan is an oncologist and physician-scientist, a doctor particularly focused on research. She cares for patients with solid organ tumors who are seeking or enrolled in immunotherapy clinical trials (studies of promising new treatments). She has a special interest in digestive system cancers.

Keenan's research investigates various immunotherapy approaches to fighting cancer, including checkpoint inhibitors (drugs that prevent an immune system response that may otherwise allow cancer cells to evade destruction), cellular therapies, bispecific antibodies (parts of lab-produced antibodies that bind to T cells and tumors so that cancer cells are directly targeted) and other new treatments.

Keenan earned her medical degree and a doctorate in immunology at the Johns Hopkins University School of Medicine. At UCSF, she completed a residency in internal medicine and a fellowship in hematology and oncology.

  • Board Certifications

    American Board of Internal Medicine, Medical Oncology, 2021

  • Fellowships

    UCSF, Hematology - Oncology, 2021

  • Residencies

    UCSF, Internal Medicine, 2017

  • Internship

    UCSF, Internal Medicine, 2016

  • Degree

    Johns Hopkins University School of Medicine, 2015

  • Languages

    English

I help patients with cancer learn whether an immunotherapy clinical trial is right for them and research better treatments using the immune system.

Where I see patients (1)

    Selected research

    See all research
    Decorative Caduceus

    Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With A...

    Quantify the desirability of a dose in terms of toxicity-efficacy tradeoff during the dose escalation portion of the study

    Recruiting

    Decorative Caduceus

    A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma

    Determine if treatment with AZD5851 is safe and tolerable through assessment of DLTs, AEs, SAEs and changes from baseline in vital signs, ECGs, and laboratory parameters

    Recruiting

    Decorative Caduceus

    DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lun...

    according to RECIST v 1.1 by investigator assessment from the date of treatment start until the earliest date of disease progression, death, or last evaluable tumour assessment before start of subsequent anti-cancer therapy, loss ...

    Recruiting

    Decorative Caduceus

    A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas

    Evaluate the safety and tolerability of ATG-031

    Recruiting

    Decorative Caduceus

    A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab f...

    Dose escalation

    Recruiting

    Contact me

    Share